ArticleThe Journal of veterinary medical science2025
Generation and characterization of feline colorectal adenocarcinoma organoids as a preclinical model.
Article in The Journal of veterinary medical science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Bladder organoid conditioned media enhances myoblast proliferation under serum free conditions.Scientific reports · 2026Article
- Perspective: from pathogenesis to treatment in veterinary science through organoid disease modelling.Frontiers in veterinary science · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Feline colorectal adenocarcinoma (FCC) is a locally invasive, highly metastatic malignant gastrointestinal tumor of colon or rectal mucosa in cats. When detected early, surgical resection may provide a promising prognosis. However, no clinical symptoms are observed in the early stages, and distant metastases or peritoneal dissemination are often already present at diagnosis. Therefore, after removal of the primary lesion, follow-up systemic therapy using anticancer drugs is required. However, the drugs currently used for FCC are not sufficiently effective in improving the prognosis, and it is necessary to develop novel and relevant preclinical models that accurately represent the disease. In this study, we developed three-dimensional culture models (organoids) from four FCC cases and examined their histopathological characteristics and drug-sensitivity profiles. FCC organoids were successfully generated and recapitulated the histological structure of the original tumor tissues. Furthermore, the FCC organoids expressed common markers (CK20 and CDX2) of FCC and exhibited tumorigenesis in vivo in mice. Cell viability assay showed that the FCC organoid lines exhibited different sensitivities to carboplatin, doxorubicin, and toceranib. Interestingly, the response of FCC organoids to toceranib varied among the lines and correlated well with the expression level of VEGFR-2, one of the target molecules of toceranib. These results suggested that FCC organoids can be used as preclinical models to advance molecular and therapeutic FCC research.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.